<?xml version='1.0'?>
<!DOCTYPE art SYSTEM 'http://www.biomedcentral.com/xml/article.dtd'>
<art>
   <ui>ar2227</ui>
   <ji>ARJ</ji>
   <fm>
      <dochead>Poster presentation</dochead>
      <bibl>
         <title>
            <p>IL-21 modulates cytokine levels in murine collagen-induced arthritis and contributes to disease pathology</p>
         </title>
         <aug>
            <au id="A1">
               <snm>Young</snm>
               <fnm>DA</fnm>
               <insr iid="I1"/>
            </au>
            <au id="A2">
               <snm>Hegen</snm>
               <fnm>M</fnm>
               <insr iid="I1"/>
            </au>
            <au id="A3">
               <snm>Ma</snm>
               <fnm>H</fnm>
               <insr iid="I1"/>
            </au>
            <au id="A4">
               <snm>Napierata</snm>
               <fnm>L</fnm>
               <insr iid="I1"/>
            </au>
            <au id="A5">
               <snm>Lamothe</snm>
               <fnm>J</fnm>
               <insr iid="I1"/>
            </au>
            <au id="A6">
               <snm>Senices</snm>
               <fnm>M</fnm>
               <insr iid="I1"/>
            </au>
            <au id="A7">
               <snm>Lowe</snm>
               <fnm>L</fnm>
               <insr iid="I1"/>
            </au>
            <au id="A8">
               <snm>Collins</snm>
               <fnm>M</fnm>
               <insr iid="I1"/>
            </au>
            <au id="A9">
               <snm>Nickerson-Nutter</snm>
               <fnm>C</fnm>
               <insr iid="I1"/>
            </au>
         </aug>
         <insg>
            <ins id="I1">
               <p>Inflammation, Wyeth Research, Cambridge, MA, USA</p>
            </ins>
         </insg>
         <source>Arthritis Research &amp; Therapy</source>
         <supplement>
            <title>
               <p>6<sup>th </sup>Global Arthritis Research Network (GARN) Meeting</p>
            </title>
            <editor>Steffen Gay and Peter E Lipsky</editor>
            <note>Meeting abstracts</note>
         </supplement>
         <conference>
            <title>
               <p>6<sup>th </sup>Global Arthritis Research Network (GARN) Meeting</p>
            </title>
            <location>Zurich, Switzerland</location>
            <date-range>10&#8211;13 May 2007</date-range>
            <url>http://www.ciaomed.org/garn.cfm</url>
         </conference>
         <issn>1478-6354</issn>
         <pubdate>2007</pubdate>
         <volume>9</volume>
         <issue>Suppl 3</issue>
         <fpage>P1</fpage>
         <url>http://arthritis-research.com/content/9/S3/P1</url>
         <xrefbib>
            <pubidlist>
               <pubid idtype="pmpid">17967205</pubid>
               <pubid idtype="doi">10.1186/ar2227</pubid>
            </pubidlist>
         </xrefbib>
      </bibl>
      <history>
         <pub>
            <date>
               <day>19</day>
               <month>10</month>
               <year>2007</year>
            </date>
         </pub>
      </history>
      <cpyrt>
         <year>2007</year>
         <collab>BioMed Central Ltd</collab>
      </cpyrt>
   </fm>
   <bdy>
      <sec>
         <st>
            <p>Background</p>
         </st>
         <p>IL-21 is secreted by activated T cells and modulates immune cell functions with both proinflammatory and anti-inflammatory effects. IL-21 receptor (IL-21R), homologous to IL-2R&#946; and IL-4R&#945;, associates with the gamma common chain upon ligand binding. It was recently described that IL-21R is overexpressed in the inflamed synovial membrane and on leucocytes of rheumatoid arthritis patients.</p>
      </sec>
      <sec>
         <st>
            <p>Objective</p>
         </st>
         <p>Previously we have shown that blockade of the IL-21 pathway with soluble IL-21R-Fc resulted in a reduction of clinical signs of arthritis in rodent models. To understand potential mechanisms of IL-21 regulation in arthritis, we analyzed serum immunoglobulin levels, and cytokine expression in the paws, serum, and collagen-restimulated splenocytes, in response to IL-21 pathway blockade.</p>
      </sec>
      <sec>
         <st>
            <p>Methods</p>
         </st>
         <p>Arthritis was induced in DBA/1 male mice with bovine type II collagen. Animals were treated with either soluble mIL-21R-Fc, which neutralizes murine IL-21 bioactivity, with TNFRII-Fc or with control IgG. Spleens from each group of treated mice were cultured <it>in vitro </it>with collagen and assayed for cytokine secretion. Cytokines and anticollagen-specific IgG levels were also measured in the serum by ELISA. Cytokine mRNA levels in the paws were evaluated by quantitative PCR analysis.</p>
      </sec>
      <sec>
         <st>
            <p>Results</p>
         </st>
         <p>Treatment of mice with IL-21R-Fc or TNFRII-Fc reduced clinical and histological signs of collagen-induced arthritis. IL-6 mRNA in paws and serum IL-6 levels were decreased after IL-21R-Fc treatment. IFN&#947; mRNA was increased in paws of IL-21R-Fc-treated mice. Collagen-specific spleen cell responses from IL-21R-Fc-treated mice exhibited increased IFN&#947; and IL-2, and reduced IL-6 and IL-17 levels. Serum levels of total IgG<sub>1 </sub>were also reduced in response to IL-21R-Fc treatment.</p>
      </sec>
      <sec>
         <st>
            <p>Conclusion</p>
         </st>
         <p>These data demonstrate a role for IL-21 in the modulation of collagen-specific T-cell responses and the pathology of arthritis, supporting a rationale for blockade of the IL-21 pathway in rheumatoid arthritis.</p>
      </sec>
   </bdy>
</art>
